Eli Lilly's GLP-1 drugs boost revenue and forecast

TITLE: Eli Lilly's GLP-1 drugs boost revenue and forecast

Big move in AI today. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound — and it could change how you think about this space. Here is what happened and why it matters.

So here is the first thing — Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge. Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.

Meanwhile — Lilly’s revenue soars 48%, driven by demand of its GLP-1s. Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

And then there is this — CVS blows past estimates, hikes guidance as insurance unit continues to improve. CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.

The bigger picture is that these updates keep pointing back to lilly, zepbound. That is why Eli Lilly's GLP-1 drugs boost revenue and forecast has momentum right now.

The real takeaway is not just one headline. This story touches lilly, zepbound, which means Eli Lilly's GLP-1 drugs boost revenue and forecast has wider impact for creators, teams, and everyday AI users.

That is the short version of what is happening with Eli Lilly's GLP-1 drugs boost revenue and forecast. If you found this useful, follow for more AI updates that actually make sense.

- Source 1: Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

- Source 2: Lilly’s revenue soars 48%, driven by demand of its GLP-1s

- Source 3: CVS blows past estimates, hikes guidance as insurance unit continues to improve